ONC · BeOne Medicines Ltd.
$346.51
+1.38% last session
End-of-day data · close of 2026-09-11
Market cap
$39B
Enterprise value
$36B
Trailing P/E
63.0
Forward P/E
33.2
Dividend yield
—
Beta
0.52
Avg volume
0M
Employees
12K
Daily Change %
1.38%
5 Days Change
-2.03%
10 Days Change
-2.39%
30 Days Change
-2.30%
60 Days Change
17.51%
Month to Day Change
-2.13%
Year to Day Change
15.53%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ONC
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
Barclays
Overweight$415
+21.4% vs priceRBC Capital
Outperform$450
+31.7% vs priceJP Morgan
Overweight$425
+24.3% vs priceJefferies
Buy$380
+11.2% vs priceWells Fargo
Overweight$400
+17.0% vs priceCitigroup
Buy$405
+18.5% vs priceMorgan Stanley
Overweight$383
+12.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Barclays | Maintains | Overweight | $407 → $415 |
| 2026-08-06 | TD Cowen | Maintains | Buy | $424 → $454 |
| 2026-08-06 | RBC Capital | Maintains | Outperform | $451 → $450 |
| 2026-08-06 | Truist Securities | Maintains | Buy | $416 → $418 |
| 2026-08-06 | Guggenheim | Maintains | Buy | $420 → $430 |
| 2026-08-06 | Barclays | Maintains | Overweight | $403 → $407 |
| 2026-08-06 | Citizens | Maintains | Market Outperform | $396 → $405 |
| 2026-07-23 | JP Morgan | Maintains | Overweight | $415 → $425 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.4% above the 50-day MA ($338.49).
- Price vs 200-day MA: Trading 9.0% above the 200-day MA ($317.79).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-4.71) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($260.27) and high ($377.47).
ONC Price Chart
Loading chart for ONC…
Fundamentals
About BeOne Medicines Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
ROIV
Roivant Sciences Ltd.
$30B 92.7% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.